使用tafenoquine进行疟疾化学预防:一项随机化研究
B Lell1, J F Faucher, M A Missinou
1Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon.
Lancet (London, England)
|July 8, 2000
概括
塔费诺奎因证明了疟疾化学预防的有效性和安全性. 这项研究发现,它在年轻成年人中耐受性良好,有效预防Plasmodium falciparum疟疾.
科学领域:
- 热带医学 热带医学
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 塔费诺昆是普里马昆的类似物,由于其长半衰期和对肝脏阶段寄生虫的活性,在疟疾化学预防中具有潜在的优势.
- 评估不同剂量的tafenoquine的疗效和安全性对于其在疟疾预防策略中的潜在采用至关重要.
研究的目的:
- 为了评估不同剂量的tafenoquine治疗疟疾的疗效和安全性.
- 为了比较tafenoquine与安慰剂在预防Plasmodium falciparum感染方面的有效性.
主要方法:
- 一项随机,双盲研究,涉及426名符合条件的参与者,年龄在12-20岁,在加,疟疾流行地区.
- 参与者每天接受tafenoquine (31.25毫克至250毫克) 或安慰剂3天,治疗治疗后.
- 通过在56日和77日监测阳性血涂片来评估有效性,并在整个70天的随访期间记录了不良事件.
主要成果:
- 到第77天,在250毫克塔芬诺基因组中没有观察到阳性血液涂抹,而在安慰剂组中只有14例.
- 与安慰剂相比,tafenoquine 125 mg 和 62.5 mg 组的阳性血涂片 (分别为 1 和 3) 显著减少.
- 在治疗组和安慰剂组之间报告的不良事件数量没有显著差异.
结论:
- 塔费诺昆是一种有效且耐受良好的抗疟疾药物.
- 这些发现支持tafenoquine的潜力,以取代现有的疟疾化学预防药物.
- 较高剂量的tafenoquine在预防疟疾感染方面表现出更高的疗效.
相关概念视频
01:29Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
01:28Toxoplasmosis
Toxoplasmosis, a zoonotic disease caused by the protozoan Toxoplasma gondii, poses significant public health challenges globally due to its high seroprevalence and varied clinical manifestations. As an obligate intracellular parasite, T. gondii can infect all warm-blooded vertebrates, but felids are its only definitive hosts, shedding unsporulated oocysts into the environment. Humans typically acquire the infection through ingestion of tissue cysts in undercooked meat or oocysts from...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...